Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB
Neuroscientific Biopharmaceuticals — Investor Presentation (May 2026)
16 slides from Neuroscientific Biopharmaceuticals's investor presentation, May 26, 2026
Slide 1: Next generation stem cell solution for severe Crohn's disease
ASX:NSB For personal use only Next generation stem cell solution for severe Crohn’s disease Nathan Smith | Chief Executive Officer Investor Presentation May 2026
Slide 2: Disclaimers
Disclaimers For personal use only Presentation Information Forward Looking Statements This presentation has been prepared by NeuroScientific Biopharmaceutic als Ltd (ASX: NSB) based on This presentation c ontains certain forward-looking statements that are based on the Company’s management’s informa
Slide 3: Company Snapshot
Company Snapshot For personal use only Corporate Share Information Capital Structure & Cash On Hand As at 25 May 2026 ORDINARY SHARES PERFORMANCE SHARES OPTIONS SHARE PRICE A$0.09 CAPITAL 332.6 million 57.1 million 48.25 million MARKET CAPITALISATION ~A$31.26 million CASH ~$5.68 million (31/3/2026)
Slide 4: Living with severe Crohn's Disease
Living with severe Crohn's Disease For personal use only Every outing requires planning Fear of sudden flare-ups Daily life becomes planned around Unpredictable symptoms create daily access to facilities and bathrooms. anxiety. Strict diets and constant fatigue Social isolation and anxiety Daily man
Slide 5: A Large Market with Significant Unmet Need
A Large Market with Significant Unmet Need For personal use only Large patient population, rising burden, limited durable treatment options ! US$13B+ 6-8M ~30% 0 Global Crohn’s Patients with Crohn’s Become refractory Treatment options once Disease market1,2 Disease globally1,2 to standard standard t
Slide 6: NSB's approach to this problem
NSB’s approach to this problem For personal use only Developing a solution for the Crohn’s problem 78 2026 Patient focused Strong prior Fistulising Crohn’s Planned treatment clinical results SAS program Phase 2 trial Treatment options are 78%1 of refractory Real patient data from Phase 2 clinical tr
Slide 7: Introducing StemSmart
Introducing StemSmart For personal use only Purpose-built Mesenchymal Stem Cell (MSC) therapy for patients with limited options¹ Activated MSC Designed for Home to inflammation sites and Optimised to enhance severe inflammation modulate the immune response therapeutic activity Targets Developed for
Slide 8: Significant Clinical Response
Significant Clinical Response For personal use only Demonstrated in Previous Clinical Trial with Refractory Crohn’s Patients 78% 44% demonstrated achieved clinical response*¹ remission**¹ StemSmart *defined as reduction in Crohn’s disease **defined as reduction in CDAI activity index (CDAI) by >100
Slide 9: Special Access Program – StemSmart
Special Access Program1,2 – StemSmart For personal use only For Patients with Fistulising Crohn’s Disease – a significant unmet medical need 4/5 patients achieved a clinical response 3,4 (≥50% fistula closure or discharge reduction) What does this mean for NSB? Special Access Scheme Fistulising Croh
Slide 10: Clinical Program
Clinical Program¹ For personal use only Preparations in progress for Phase 2 Clinical Trials Fistulising Crohn's Disease Refractory Crohn's Disease Phase 2 clinical trial in Australia only Phase 2 clinical trial in US & Australia Australian TGA Clinical Trial Notification pathway US FDA Investigatio
Slide 11: Securing the StemSmart Supply Chain
Securing the StemSmart Supply Chain¹ For personal use only Partnering with leading manufacturer for clinical & commercial scale Patented StemSmart Manufacturing Process Bone marrow source Isolate MSCs Cell expansion StemSmart activation Harvest, QC & cryostore Patient infusion Tech Transfer to Q-Gen
Slide 12: Strong Global IP Position & Protection
Strong Global IP Position & Protection For personal use only Patented manufacturing process with freedom to operate Active Patents ● “Cell Culture Method” for StemSmart technology – Dr Marian Sturm ○ Right to Exploit with Acquisition of Isopogen Pty Ltd1 ○ Granted in 14 Markets including Australia,
Slide 13: Key Milestones
Key Milestones1,2,3,4 CURRENT POSITION For personal use only ACHIEVED TO DATE Phase 2 preparation activities UPCOMING MILESTONES Significant progress building a underway Executing on the next phase of strong foundation development StemSmart acquisition completed TGA Licensure at Q-Gen Secured patent
Slide 14: Leadership & Advisory Strength
Leadership & Advisory Strength¹ For personal use only NATHAN SMITH DR MARIAN STURM PROF CATHERINE COLE BSc MBBS, FRACP, FRCPA FFSc (RCPA), PhD, MSc, BSc Hons CHIEF EXECUTIVE OFFIC ER CHIEF SCIENTIFIC OFFICER CHIEF MEDICAL OFFICER 25+ years in biologics and cell & 40+ years in cellular therapy 35 yea
Slide 15: Investment Highlights
Investment Highlights For personal use only 01 02 03 04 Key leadership and Patented StemSmart Proven Clinical Commercialisation experience¹ Tech Platform² Efficacy³ Pathway⁴ 1.ASX Announcement (6 November 2025) – “NeuroScientific Appoints Clinical & Scientific Advisory Board.” 2.ASX Announcement (16
Slide 16: Contact
ASX:NSB For personal use only Contact Nathan Smith Dr Anton Uvarov Chief Executive Officer Founding Non-Executive Director +61 477 738 404 +61 8 6268 2641 nsmith@neuroscientific.com au@neuroscientific.com 1 5
NeuroScientific Biopharmaceuticals — Investor Presentation (May 2026) on 6ix